The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses

Antiviral Research

Volumn 33, Issue 2, 1997, Pages 109-115

  Kinjerski, Tracy L ^a   Buckheit Jr , Robert W ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

HIV 1; Resistance; Reverse transcriptase inhibitors

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; CARBOXIN; CELL LINE; DRUG RESISTANCE, MICROBIAL; GENETIC HETEROGENEITY; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031014263     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(96)01008-X     Document Type: Article

References (34)

1. Bader, J.P., McMahon, J.B., Schultz, R.J., Narayanan, V.L., Pierce, J.B., Harrison, W.A., Weislow, O.S., Midelfort, C.F., Stinson, S.F. and Boyd, M.R. (1991) Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88, 6740-6744.
2. Balzarini, J., Karlsson, A. and De Clercq, E. (1993a) Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol. Pharmacol. 44, 694-701.
3. Balzarini, J., Karlsson, A., Perez-Perez, M.J., Camarasa, M.J. and De Clercq, E. (1993b) Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196, 576-585.
4. Balzarini, J., Karlsson, A., Sardana, V.V., Emini, E.A., Camarasa, M.J. and De Clercq, E. (1994) Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 91, 6599-6603.
5. Balzarini, J., Jonckheere, H., Harrison, W.A., Dao, D.C., Anne, J., De Clercq, E. and Karlsson, A. (1995a) Oxathiin carboxanilide derivatives: a class of nonnucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 6, 169-178.
6. Balzarini, J., Perez-Perez, M.J., Velazquez, S., San-Felix, A., Camarasa, M.J., De Clercq, E. and Karlsson, A. (1995b) Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA 92, 5470-5474.
7. Buckheit, R.W. Jr., Hollingshead, M.G., Germany-Decker, J., White, E.L., McMahon, J.B., Allen, L.B., Ross, L.J., Decker, W.D., Westbrook, L. and Shannon, W.M. (1993) Thiazolobenzimidazole: biological and biochemical antiretroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 21, 247-265.
8. Buckheit, R.W. Jr., Fliakas-Boltz, V., Decker, W.D., Roberson, J.L., Pyle, C.A., White, E.L., Bowdon, B.J., McMahon, J.B., Boyd, M.R. and Bader, J.P. et al. (1994) Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25, 43-56.
9. Buckheit, R.W. Jr., Fliakas-Boltz, V., Decker, W.D., Roberson, J.L., Stup, T.L., Pyle, C.A., White, E.L., McMahon, J.B., Currens, M.J. and Boyd, M.R. et al. (1995a) Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 117-132.
10. Buckheit, R.W. Jr., Fliakas-Boltz, V., Yeagy-Bargo, S., Weislow, O., Mayers, D.L., Boyer, P.L., Hughes, S.H., Pan, B.C., Chu, S.H. and Bader, J.P. (1995b) Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 210, 186-193.
11. Buckheit, R.W., Jr., Kinjerski, T.L., Fliakas-Boltz, V., Russell, J.D., Stup, T.L., Pallansch, L.A., Brouwer, W.G., Dao, D.C., Harrison, W.A. and Schultz, R.J. et al. (1995e) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39, 2718-2727.
12. Cohen, K.A., Hopkins, J., Ingraham, R.H., Pargellis, C., Wu, J.C., Palladino, D.E., Kinkade, P., Warren, T.C., Rogers, S. and Adams, J. (1991) Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcrip-tase. J. Biol. Chem. 266, 14670-14674.
13. Condra, J.H., Emini, E.A., Gotlib, L., Graham, D.J., Schlabach, A.J., Wolfgang, J.A., Colonno, R.J. and Sardana, V.V. (1992) Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents Chemother. 36, 1441-1446.
14. DeVreese, K., Debyser, Z., Vandamme, A.-M., Pauwels, R., Desmyter, J., De Clercq, E. and Anne, J. (1992) Resistance to human immunodeficiency virus type I reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology 900-904.
15. Gendelman, H.E., Theodore, S.T., Willey, R., McCoy, J., Adachi, A., Mervis, R.J., Venkatesan, S. and Martin, M.A. (1987) Molecular characterization of a polymerase mutant human immunodeficiency virus. Virology 160, 323-329.
16. Goff, S.P. (1990) Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immuno. Def. Syn. 3, 817-831.
17. Goldman, M.E., Nunberg, J.H., O'Brien, J.A., Quintero, J.C., Schleif, W.A., Freund, K.F., Gaul, S.L., Saari, W.S., Wai, J.S. and Hoffman, J.M. et al. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88, 6863-6867.
18. Grob, P.M., Wu, J.C., Cohen, K.A., Ingraham, R.H., Shih, C.K., Hargrave, K.D., McTague, T.L. and Merluzzi, V.J. (1992) Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8, 145-152.
19. Jacobo-Molina, A., Ding, J., Nanni, R.G., Clark, A.D., Lu, X., Tantillo, C., Williams, R.L., Kamer, G., Ferris, A.L. and Clark, P. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double stranded DNA at 3.0 A resolution shows bent DNA. Proc. Nat. Acad. Sci. USA 90, 6320-6324.
20. Kashman, Y., Gustafson, K.R., Fuller, R.W., Cardellina, J.H., McMahon, J.B., Currens, M.J., Buckheit, R.W. Jr., Hughes, S.H., Cragg, G.M. and Boyd, M.R. (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum [published erratum appears in J. Med. Chem. 1993 Apr 16; 36(8):1110]. J. Med. Chem. 35, 2735-2743.
21. Kinjerski, T.L., Pallansch, L.A. and Buckheit, R.W. Jr. (1996) Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogs: evaluation of variables in the resistance selection process. Antiviral Chem. Chemother. 7: 261-269.
22. Klunder, J.M., Hargrave, K.D., West, M., Cullen, E., Pal, K., Behnke, M.L., Kapadia, S.R., McNeil, D.W., Wu, J.C. and Chow, G.C. (1992) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J. Med. Chem. 35, 1887-97.
23. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790.
24. Lockey, T.D., Slobod, K.S., Rencher, S.D., Srinivas, R.V. and Hurwitz, J.L. (1996) Fluctuating diversity in the HTLV-IIIB virus stock: implications for neutralization and challenge experiments. AIDS Res. Hum. Retrov. 12, 1297-1299.
25. Maass, G., Immendoerfer, U., Koenig, B., Leser, U., Mueller, B., Goody, R. and Pfaff, E. (1993) Viral resistance nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37, 2612-7.
26. McMahon, J.B., Gulakowski, R.J., Weislow, O.S., Schultz, R.J., Narayanan, V.L., Clanton, D.J., Pedemonte, R., Wassmundt, F.W., Buckheit, R.W. Jr. and Decker, W.D. (1993) Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37, 754-760.
27. Mellors, J.W., Larder, B.A. and Schinazi, R.F. (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3, 8-13.
28. Merluzzi, V.J., Hargrave, K.D., Labadia, M., Grozinger, K., Skoog, M., Wu, J.C., Shih, C.K., Eckner, K., Hattox, S. and Adams, J. et al. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor [published erratum appears in Science 1991 Jan 25; 251(4992):362]. Science 250, 1411-1413.
29. Nanni, R.G., Ding, J., Jacobo-Molina, A., Hughes, S.H. and Arnold, E. (1993) Review of HIV-1 reverse transcriptase three dimensional structure: implications for drug design. Perspect. Drug Discovery Design 1, 129-150.
30. Nunberg, J.H., Schleif, W.A., Boots, E.J., O'Brien, J.A., Quintero, J.C., Hoffman, J.M., Emini, E.A. and Goldman, M.E. (1991) Viral resistance to human immunodeficiency virus type !-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65, 4887-4892.
31. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M.J., Breslin, H.J., Raeymaeckers, A., Van Gelder, J., Woestenborghs, R. and Heykants, J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470-474.
32. Richman, D., Rosenthal, A.S., Skoog, M., Eckner, R.J., Chou, T.C., Sabo, J.P. and Merluzzi, V.J. (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35, 305-308.
33. Romero, D.L., Busso, M., Tan, C.K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff, P.A., Downey, K.M., So, A.G. and Resnick, L. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88, 8806-8810.
34. Rose, R.E., Gong, Y., Greytok, J.A., Bechtold, C.M., Terry, B.J., Robinson, B.S., Alam, M., Colonno, R.J. and Lin, P. (1996) Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93, 1648-1653.